Breaking News Headlines Today | Ground News

See every side of every news story

cancernetwork.com image

News from cancernetwork.com

Ground News rates cancernetwork.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is cancernetwork.com credible or reliable? Our Factuality score answers both of those questions. When it comes to cancernetwork.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about cancernetwork.com

Where is cancernetwork.com located?cancernetwork.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top cancernetwork.com News

Two Drugs Approved for NPM1-Mutated Leukemia

United States · United States

Two Drugs Approved for NPM1-Mutated Leukemia

80% Center coverage: 5 sources

(MedPage Today) -- The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1-mutated...See the Story

Key HER2-Positive Breast Cancer Therapy Gets Its First Biosimilar

Cancer · United States

Key HER2-Positive Breast Cancer Therapy Gets Its First Biosimilar

100% Center coverage: 1 sources

(MedPage Today) -- The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer. FDA granted the targeted agent an...See the Story

This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data

Breast Cancer · United States

This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data

A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.See the Story

Breaking News Topics Related to cancernetwork.com